[Ip-health] Novartis, Dana Farber, Oregon Health & Science University Wait 18 Years to Disclose NIHFunding in Key Gleevec Patent | Bill of Health
jfortunak at comcast.net
Fri Oct 11 09:58:28 PDT 2019
CONGRATULATIONS JAMIE, well done indeed!!
Sent from Mail for Windows 10
From: James Love
Sent: Friday, October 11, 2019 12:09 PM
Subject: [Ip-health] Novartis, Dana Farber,Oregon Health & Science University Wait 18 Years to Disclose NIHFunding in Key Gleevec Patent | Bill of Health
After 18 years, Novartis gets around to disclosing NIH funding in a Gleevec
This is a story about U.S. patent number 6,958,335, and how it took more
than 18 years for Novartis to acknowledge National Institutes of Health
(NIH) funding in a key patent for Gleevec, allowing Novartis to shape the
narrative regarding its role in the development of Gleevec, and also to
avoid demands that Novartis make the invention “available to the public on
reasonable terms,” which is an obligation under the Bayh-Dole Act.
Ip-health mailing list
Ip-health at lists.keionline.org
This email has been checked for viruses by Avast antivirus software.
More information about the Ip-health